Drug Profile
TBI 302
Alternative Names: Haemoglobin-conjugated floxuridine; HRC 204; TBI-302Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Hemosol BioPharma
- Developer Therapure Innovations
- Class Antineoplastics; Deoxyribonucleosides; Haemoglobins; Nucleosides; Protein-drug conjugates; Pyrimidine nucleosides
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Liver cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Liver-cancer in USA (IV, Infusion)
- 10 Sep 2020 Phase-I clinical trials in Liver cancer in USA (IV) (Therapure Biopharma pipeline, September 2020)
- 28 Jul 2018 No recent reports of development identified for preclinical development in liver cancer in Canada (IV, Infusion)